All Updates

All Updates

icon
Filter
Funding
Peptone raises USD 40 million in Series A
AI Drug Discovery
Jun 9, 2022
This week:
Partnerships
T-Mobile partners with OpenAI to develop AI-powered customer service platform
Generative AI Applications
Today
Partnerships
Runway partners with Lionsgate to develop AI video tools using studio's movie catalog
Generative AI Applications
Yesterday
Funding
QMill raises EUR 4 million in seed funding to provide quantum computing industrial applications
Quantum Computing
Yesterday
Product updates
QuiX Quantum launches 'Bia' quantum cloud computing service for quantum solutions
Quantum Computing
Yesterday
Partnerships
Oxford Ionics and Infineon Technologies partner to build portable quantum computer for Cyberagentur
Quantum Computing
Yesterday
Product updates
Partnerships
Tencent Ai Lab launches EzAudio AI for text-to-audio generation with Johns Hopkins University
Foundation Models
Yesterday
Funding
TON secures USD 30 million in investment from Bitget and Foresight Ventures
Web3 Ecosystem
Yesterday
Funding
Hemi Labs raises USD 15 million in funding to launch blockchain network
Web3 Ecosystem
Yesterday
Product updates
Fivetran launches Hybrid Deployment for data pipeline management
Machine Learning Infrastructure
Yesterday
Product updates
Fivetran launches Hybrid Deployment for data pipeline management
Data Infrastructure & Analytics
Yesterday
AI Drug Discovery

AI Drug Discovery

Jun 9, 2022

Peptone raises USD 40 million in Series A

Funding

  • UK-based protein discovery company Peptone has raised USD 40 million in a Series A funding round co-led by F-Prime Capital and Bessemer Venture Partners, with participation from Walden Catalyst Ventures, Novartis’s venture arm dRX Capital, and others. This round brings the company’s total funds raised to date to USD 42 million.

  • The proceeds will be injected into the company’s growth efforts including building its laboratory facilities in Switzerland, acquiring advanced imaging machinery and equipment for the facility, expanding its team to 25 people from 14 at present, and identifying drug candidates for five protein targets to advance toward pre-clinical validation in 14 months.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.